Tempus AI, Inc. Class A Common Stock Q3 2025 Earnings Recap

Tempus AI reported a strong Q3 2025, achieving robust growth in both Genomics and Data Licensing, culminating in the company’s first positive adjusted EBITDA.

Key Takeaways

• Genomics volume surged 33% overall, with notable growth in Hereditary (37%) and Oncology (27%).
• The Data Licensing segment grew 38%, adding $150 million in total contract value.
• Achieved positive adjusted EBITDA for the first time, a significant milestone after 10 years, despite expenses from the Paige acquisition.
• Growth is underpinned by improved sales efficiency and advancements in their integrated technology offerings.
• Adjusted EBITDA for the full year is now expected to be slightly positive, even accounting for additional costs from acquisitions.